According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...

Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...

Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...

FDA finds benzene contamination, Tronox to close a pigment plant, Sofinnova launches a European biotech fund, and more ...

The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive ...

The Supreme Court last year blocked a previous settlement proposal from Purdue, arguing that the plan would afford the ...

Each year, millions of people in America are prescribed a medicine for acute pain.Now, for the first time in over 20 years, ...

Pershing is hopeful it’ll make an impact in reducing addiction but wants to see the new drug in use before casting a final judgment. “When oxycodone was released, Purdue Pharma told everyone this was ...

The FDA's landmark approval of Journavx (suzetrigine)?the first non-opioid pain reliever in over two decades?represents a breakthrough in pain management. This breakthrough underscores the urgent need ...